Skip to content

EVOKE PHARMA, INC.

CIK 0001403708

← back to feed
Revenue (TTM)
$13.77M
+97.8% YoY Q3 Nov 2025
Net Income (TTM)
−$5.35M
+31.3% YoY Q3 Nov 2025
EPS Diluted (TTM)
−$2.52
−20.6% YoY Q3 Nov 2025
Gross Margin
—
Q3 Nov 2025
Operating Margin
-38.4%
Q3 Nov 2025
Net Margin
-38.8%
Q3 Nov 2025
Free Cash Flow (TTM)
—
Q3 Nov 2025
Cash
$11.58M
Q3 Nov 2025
Total Debt
$8.08M
Q3 Nov 2025
Shares Outstanding
1.72M sh
Q3 Nov 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings